[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532131":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":12,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":12,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":12,"overallStatus":36,"whyStopped":12,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"San Diego State University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","NO_INTERVENTION","Participants will consume their normal daily diet.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Creatine supplementation","EXPERIMENTAL","The intervention group will consume their usual diet plus 5 grams of creatine for the first four days following the initial meeting, and then 3 grams of creatine once per day thereafter until asymptomatic.",[18],"Dietary Supplement: Creatine",[20],{"type":21,"name":22,"description":14,"armGroupLabels":23,"otherNames":12},"DIETARY_SUPPLEMENT","Creatine",[14],[25],{"name":26,"affiliation":5,"role":27},"Michelle Weber Rawlins","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":12,"email":33},"Michelle Weber Rawlins, PhD, ATC","CONTACT","619-594-1924","mrawlins@sdsu.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","San Diego","California","92812","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.16472,32.71571,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":12,"email":33},"Michelle L Weber Rawlins, PhD,ATC","(619) 594-1924",{"type":53,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100532131","creatine-supplementation-in-concussion-recovery-100532131",false,"NCT06208813","Creatine Supplementation in Concussion Recovery","Assigned Creatine Ingestion With Usual Diet or Usual Diet Alone.","CSCR","Inclusion Criteria:\n\n* 18-35 years old with a diagnosed concussion within 72 hours post-injury\n\nExclusion Criteria:\n\n* Learning disability, renal disease, mental behavior or migraine history, and current creatine use or have not taken creatine in the past 6 weeks","ALL","18 Years","35 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"NA","The proposed study aims to compare concussion recovery in those supplementing creatine and those not supplementing creatine. Specific aim 1: To compare number of days until asymptomatic between those taking creatine vs. those not taking creatine following a concussion. Hypothesis: The investigators hypothesize that individuals taking creatine will become asymptomatic sooner than those not taking creatine.Specific aim 2: To compare typical concussion assessment scores (i.e., symptom score, mental status, neurocognition, balance, motor coordination, and visual performance) between those taking creatine vs those not taking creatine following a concussion once asymptomatic.Hypothesis: The investigators hypothesize that individuals taking creatine will have better symptom scores, balance, mental status, and neurocognition assessment scores than those not taking creatine once asymptomatic.\n\nThe investigators will calculate descriptive statistics for all demographic, days to asymptomatic, and concussion assessments. For specific aim 1, The investigators will calculate a t-test to determine if days to asymptomatic differed in those taking creatine vs. those not taking creatine. For specific aim 2, the investigators will calculate t-tests with Bonferonni corrections to determine if concussion assessment scores (Sport Concussion Office Assessment Tool-6 assessments, CNS Vital Signs, visual assessment) differed in those taking creatine vs. those not taking creatine.",[73],"Concussion, Brain","2026-06-17",{"date":76,"type":77},"2026-06-18","ACTUAL",{"date":79,"type":77},"2024-02-01",{"date":81,"type":67},"2027-05-31",{"name":5,"class":6},1]